• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sensile Medical partners with Verily, Sanofi to develop connected insulin patch pump

June 27, 2018 By Sarah Faulkner

Sensile MedicalSwiss medical device-maker Sensile Medical announced this week that it struck a deal with Verily and Sanofi (NYSE:SNY) to develop and commercialize a connected insulin patch pump.

The pre-filled insulin patch pump will be designed primarily for people with Type II diabetes, according to the Olten, Switzerland-based company.

Each company brings its own unique strength to the partnership, according to Sensile Medical – the deal combines Sanofi’s expertise in insulin, Verily’s experience in digital healthcare tech and Sensile Medical’s skill in developing micro-pump technologies.

“Our goal is to develop a new type of pump technology that is simple to use and appropriate for people with Type II diabetes, as well as by those with Type I diabetes who are the primary users of insulin pumps today,” CEO Derek Brandt said in prepared remarks.

Sanofi and Verily already have an established business relationship. In September 2016, the two companies launched a joint venture, Onduo, in an effort to create virtual clinics for people with diabetes and their caregivers.

“It’s a problem that frankly many companies are trying to address and we think the collective capability of Verily, with their expertise in miniaturized electronics and consumer-facing apps and analytics, combined with Sanofi’s expertise in disease, therapies and understanding how patients and physicians manage diabetes, together can work to develop a novel set of solutions to tackle this epidemic,”  Rachel Sha, VP of Sanofi’s digital business development & licensing unit, told Drug Delivery Business News in an interview earlier this year.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Sanofi-Aventis, sensilemedical, Verily

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS